This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Sage Therapeutics 경영진
경영진 기준 점검 1/4
Sage Therapeutics CEO는 Barry Greene, Dec2020 에 임명되었습니다 의 임기는 4.67 년입니다. 총 연간 보상은 $7.11M, 11.7% 급여 및 88.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $869.48K 가치에 해당하는 회사 주식의 0.16% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 0.8 년과 10 년입니다.
핵심 정보
Barry Greene
최고경영자
US$7.1m
총 보수
| CEO 급여 비율 | 11.68% |
| CEO 재임 기간 | 4.7yrs |
| CEO 지분 보유율 | 0.2% |
| 경영진 평균 재임 기간 | less than a year |
| 이사회 평균 재임 기간 | 10yrs |
최근 경영진 업데이트
Recent updates
새로운 내러티브 • Mar 29
Expanding ZURZUVAE Demand Will Improve Postpartum And Neuropsych Care
Establishing ZURZUVAE as the PPD care standard should drive top-line growth through increased demand and brand visibility.Seeking Alpha • Jan 22
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Summary Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for SAGE at $7.22 per share, which seems exceedingly cheap, considering SAGE has a lot of cash, and Zurzuvae is just ramping up its sales. SAGE is now contesting the takeover, which could lead to higher follow-up bids. This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime that provides quick relief for depressive symptoms. This is why I think SAGE stock is a good buy at these levels. It seems undervalued as a standalone company or a takeover target with BIIB. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Summary The company remains a "hold" due to Biogen's unsolicited offer to acquire shares at a 30% premium, despite pipeline setbacks. The failure of the phase 2 DIMENSION study for dalzanemdor in treating cognitive impairment in Huntington's Disease highlights Sage's shrinking pipeline. Sage's financials indicate a need for additional funding in 2025, risking dilution and further financial instability. The future of SAGE-324 and SAGE-319 remains uncertain in treating patients with neurodevelopmental disorders, adding risk to the company's long-term prospects. Read the full article on Seeking AlphaSeeking Alpha • Nov 19
CNS Drug Development: Same As It Ever Was
Summary Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as well. They have a clinical trial readout in Huntington's disease later this fall, and man, that's a tough place to make your stand. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Summary Sage Therapeutics is a "sell" due to the failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's Disease. Dalzanemdor's upcoming phase 2 studies for Huntington's and Alzheimer's diseases are unlikely to succeed, given prior trial results and similar primary endpoints. Financially, Sage has enough cash to operate until 2026, but without successful trials, raising additional funds will be challenging. Despite FDA approval of Zurzuvae for postpartum depression, it won't drive long-term growth; dalzanemdor's success is crucial for shareholder value creation. Read the full article on Seeking Alpha분석 기사 • Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Jul 25
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Summary Sage Therapeutics, Inc.'s SAGE-324 failed its Phase 2b trial for essential tremor and development is discontinued. Dalzanemdor's past data in Parkinson's casts doubt on its prospects in other cognitive disorders. Zurzuvae's Q1 revenue exceeded expectations, but the market potential remains constrained by its narrow indication. Analysts are expecting $8.90 million in revenue for Q2. While Sage may exceed this, it isn't likely to move the stock much. Given clinical setbacks and limited revenue growth, I recommend downgrading Sage Therapeutics to “sell.”. Read the full article on Seeking Alpha분석 기사 • Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Sage Therapeutics, Inc. ( NASDAQ:SAGE ) is a stock...Seeking Alpha • May 30
Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patients, expected in mid-2024. Top-line data from the phase 2 DIMENSION study, using SAGE-718 for cognitive impairment in HD patients, expected late-2024. Top-line data from the phase 2 LIGHTWAVE Study, using SAGE-718 for mild cognitive impairment or mild dementia due to Alzheimer's Disease, expected late-2024. Read the full article on Seeking Alpha분석 기사 • May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
The analysts covering Sage Therapeutics, Inc. ( NASDAQ:SAGE ) delivered a dose of negativity to shareholders today, by...분석 기사 • Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Key Insights Sage Therapeutics' estimated fair value is US$29.43 based on 2 Stage Free Cash Flow to Equity Sage...Seeking Alpha • Jan 22
Sizing Up Sage Therapeutics
Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. The drug has just been launched and management has taken actions to substantially lower annual operating costs. What's ahead for Sage Therapeutics in 2024? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Today is shaping up negative for Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders, with the analysts delivering a...분석 기사 • Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Today we will run through one way of estimating the intrinsic value of Sage Therapeutics, Inc. ( NASDAQ:SAGE ) by...분석 기사 • Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 02
Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Sage Therapeutics press release (NASDAQ:SAGE): Q2 GAAP EPS of -$2.13 beats by $0.02. Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M. Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022 Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022 Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025분석 기사 • Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 24
Sage Therapeutics: Well-Funded But Uninspiring Data
Sage is well funded by Biogen. However, lead candidate SAGE-217 has not come up with strong MDD data. I continue to sit on the fence.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$301m |
| Mar 31 2025 | n/a | n/a | -US$354m |
| Dec 31 2024 | US$7m | US$831k | -US$401m |
| Sep 30 2024 | n/a | n/a | -US$338m |
| Jun 30 2024 | n/a | n/a | -US$446m |
| Mar 31 2024 | n/a | n/a | -US$503m |
| Dec 31 2023 | US$6m | US$799k | -US$541m |
| Sep 30 2023 | n/a | n/a | -US$656m |
| Jun 30 2023 | n/a | n/a | -US$592m |
| Mar 31 2023 | n/a | n/a | -US$558m |
| Dec 31 2022 | US$6m | US$761k | -US$533m |
| Sep 30 2022 | n/a | n/a | -US$510m |
| Jun 30 2022 | n/a | n/a | -US$503m |
| Mar 31 2022 | n/a | n/a | -US$484m |
| Dec 31 2021 | US$59m | US$735k | -US$458m |
| Sep 30 2021 | n/a | n/a | US$642m |
| Jun 30 2021 | n/a | n/a | US$666m |
| Mar 31 2021 | n/a | n/a | US$637m |
| Dec 31 2020 | US$836k | US$53k | US$606m |
보상 대 시장: Barry의 총 보수(USD7.11M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.67M)보다 높습니다.
보상과 수익: Barry의 보상은 회사가 적자임에도 증가했습니다.
CEO
Barry Greene (62 yo)
4.7yrs
재임 기간
US$7,112,589
보수
Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and serves as Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics,...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 4.7yrs | US$7.11m | 0.16% $ 869.5k | |
| COO & Treasurer | less than a year | US$2.60m | 0.019% $ 104.6k | |
| Senior VP | less than a year | US$1.17m | 데이터 없음 | |
| Chief Scientific Officer & Interim Head of R&D | 2yrs | 데이터 없음 | 0.049% $ 264.4k | |
| Director of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP and Chief People & Experience Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Drug Safety & Pharmacovigilance | no data | 데이터 없음 | 데이터 없음 | |
| Medical Director of Early Clinical Development | no data | 데이터 없음 | 데이터 없음 | |
| Investor Relations Officer | no data | 데이터 없음 | 데이터 없음 |
0.8yrs
평균 재임 기간
경험이 풍부한 관리: SAGE의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 0.8 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 4.8yrs | US$7.11m | 0.16% $ 869.5k | |
| Independent Director | 10.9yrs | US$167.22k | 0% $ 0 | |
| Independent Director | 11.3yrs | US$169.31k | 0.0045% $ 24.7k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chair of the Board | 9.1yrs | US$190.49k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 |
10.0yrs
평균 재임 기간
64yo
평균 나이
경험이 풍부한 이사회: SAGE의 이사회는 노련하고 경험이 풍부합니다(평균 재임 10 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/08/01 17:44 |
| 종가 | 2025/07/30 00:00 |
| 수익 | 2025/06/30 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sage Therapeutics, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |